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Abstract: Neuromyelitis optica (NMO), also known as 
Devic’s disease, is an autoimmune disorder of the central 
nervous system (CNS) in which immune system cells and 
antibodies primarily attack the optic nerves and the spinal 
cord. OX40 (CD134) is a tumor necrosis factor (TNF)-receptor 
family member expressed primarily on activated CD4+ and 
CD8+ T-cells. In an autoimmune disease, OX40 is typically 
up-regulated at sites of inflammation, and increases in the 
number of peripheral CD4+ T-cells expressing OX40. OX40 
and its ligand OX40L are key TNF members that augment 
T-cell expansion, cytokine production, and promote 
T-cell survival. The aim of this study was to evaluate and 
compare of OX40 gene expression and its serum levels in 
patients with NMO and healthy controls. Twenty sex-/age-
matched healthy controls (HC) (median age = 32 years, 
15 females/5 males) were engaged for the present study. 
Expression of OX40 at the transcript level and serum 
protein levels were measured by quantitative real-time 
polymerase chain reaction (qRT-PCR) and enzyme-linked 
immunosorbent assays, respectively. The results indicated 
OX40 expression in patients was significantly lower than 
in healthy controls (p = 0.001). However, the serum level 
of OX40 was not significantly different between groups 
(p = 0.37). In addition, the results indicated that CD134 
expression was not age-related (p = 0.041). Overall, this 
study suggests to us that OX40 levels are not a suitable 
marker for  diagnosis or treatment of NMO.
Keywords: Neuromyelitis optica (NMO); OX40; 
autoimmune.
Introduction
Neuromyelitis optica (NMO), also known as Devic’s 
disease, is an autoimmune disorder of the central 
nervous system (CNS) in which immune system cells and 
antibodies attack the optic nerves and the spinal cord. 
Like multiple sclerosis (MS), NMO is a relapsing-remitting 
disease [1, 2]. During any relapse, new damage to the 
optic nerves and/or spinal cord can lead to accumulating 
disability. Unlike MS, there is no progressive phase of this 
disease. Therefore, preventing attacks is critical to a good 
long-term outcome.
Among NMO and NMO spectrum disorder (NMOSD) 
patients, > 70% are characterized by a presence of serum 
autoantibodies against astrocyte water channel aquaporin 
4 (AQP4) on cell membranes [3, 4]. These pathogenic IgG1 
antibodies are important as they illustrate how AQP4-
specific T-cells likely participate in the pathogenesis 
of NMO [5]. Among these, there is an IgG1 autoantibody 
that is also found in patients with two related neurologic 
conditions (two-sided optic neuritis (ON) and longitudinal 
wide transverse myelitis (LETM)) that fall in the NMO range 
of diseases, [5]. Thus, there is the potential to develop 
regimens to counteract these and other antibodies - 
once the latter have been identified - as a means to help 
prevent/mitigate NMO attacks.
OX40 (CD134) is a tumor necrosis factor (TNF)-receptor 
family member expressed primarily on activated CD4+ 
and, CD8+ and regulatory T-cells (Treg cells) [6]. Normally, 
OX40 is activated by the ligand OX40L (CD134L), and 
thus functions as a T-cell co-stimulatory molecule. It is 
known that OX40-OX40L interactions can promote T-cell 
survival, including that of effector and memory T-cells, as 
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Abstract: Let F denote a eld and let V denote a vector space over Fwith nite positive dimension. Consider
a pair A, A∗ of diagonalizable F-linear maps on V, each of which acts on an eigenbasis for the other one in an
irreducible tridiagonal fashion. Such a pair is called a Leonard pair. We consider the self-dual case in which
there exists an automorphismof the endomorphismalgebra ofV that swapsA andA∗. Such anautomorphism
is unique, and called the duality A ↔ A∗. In the present paper we give a comprehensive description of this
duality. Inparticular,wedisplay an invertibleF-linearmap T onV such that themap X → TXT−1 is theduality
A ↔ A∗. We express T as a polynomial in A and A∗. We describe how T acts on 4 ags, 12 decompositions,
and 24 bases for V.
K ywords: Leonard pair, tridiagonal matrix, self-dual
Classication: 17B37, 15A21
1 Introduction
Let F denote a eld and let V denote a vector space over F with nite positive dimension. We consider a
pair A, A∗ of diagonalizable F-linear maps on V, each of which acts on an eigenbasis for the other one in an
irreducible tridiagonal fashion. Such a pair is called a Leonard pair (see [13, Denition 1.1]). The Leonard pair
A, A∗ is said to be self-dual whenever there exist an automorphism of the endomorphism algebra of V that
sw ps A and A∗. In this case such an automorphis is unique, and called the duality A ↔ A∗.
The literature containsmany examples of self-dual Leonardpairs. For instance (i) the Leonardpair associ-
atedwith an irreduciblemodule for the Terwilliger algebra of the hypercube (see [4, Corollaries 6.8, 8.5]); (ii) a
Leonard pair of Krawtchouk type (see [10, Denition 6.1]); (iii) the Leonard pair associatedwith an irreducible
module for the Terwilliger algebra of a distance-regular graph that has a spin model in the Bose-Mesner alge-
bra (see [1, Theorem], [3, Theorems 4.1, 5.5]); (iv) an appropriately normalized totally bipartite Leonard pair
(see [11, Lemma 14.8]); (v) the Leonard pair consisting of any two of a modular Leonard triple A, B, C (see [2,
Denition 1.4]); (vi) the Leonard pair consisting of a pair of opposite generators for the q-tetrahedron alge-
bra, acting on an ev luationmodule (see [5, Proposition 9.2]). The example (i) is a special case of (ii), and the
examples (iii), (iv) are pecial cases of (v).
Let A, A∗ denote a Leonard pair on V. We can determine whether A, A∗ is self-dual in the following way.
By [13, Lemma 1.3] each eigenspace of A, A∗ has dimension one. Let {θi}di=0 denote an ordering of the eigen-
values of A. For 0 ≤ i ≤ d let vi denote a θi-eigenvector for A. The ordering {θi}di=0 is said to be standard
whenever A∗ acts on the basis {vi}di=0 in an irreducible tridiagonal fashion. If the ordering {θi}di=0 is standard
then the ordering {θd−i}di=0 is also standard, and no further ordering is standard. Similar comments apply to
A∗. Let {θi}di=0 denote a standard ordering of the eigenvalues of A. Then A, A∗ is self-dual if and only if {θi}di=0
is a standard ordering of the eigenvalues of A∗ (see [7, Proposition 8.7]).
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well as enhance the production of several cytokines [7-9]. 
Studies have shown that use of anti-OX40 in the treatment 
of some autoimmune diseases imparts a potent anti-
inflammatory activity in a manner that is dependent on 
both CD4+ and CD8+ T-cells [10, 11]. Immunization models 
have also shown that the use of anti-OX40 increases 
T-cell proliferation and differentiation into expanded 
populations of effector T-cells, with concomitant changes 
in cytokine production, T-cell-mediated cytotoxicity, and 
a decrease in activation-induced cell death [11, 12].
In several autoimmune diseases (e.g., Systemic 
lupus erythmathosus [SLE], colitis), the presence of 
OX40 is up-regulated at sites of inflammation, and there 
are increases in the number of peripheral CD4+ T-cells 
expressing OX40 [13, 14]. In SLE, the expression of OX40 
on CD4+ T-lymphocytes and the serum level of OX40L may 
act as markers of lupus nephritis and it suggests there is a 
correlation between the presence of OX40 expression and 
disease severity[15]. As OX40 also promotes the colitogenic 
T-helper cell type 1 (TH1) response, its expression on 
Treg cells may be required for effective competition with 
OX40-dependent effector responses [14, 16]. In addition, 
stimulation of OX40-expressing cells after the induction of 
colitis exaggerates intestinal inflammation - presumably 
by enhancing effector lymphocyte function. Thus, it 
seems that stimulation of a host with an agonistic OX40 
antibody could increase the number of functional Treg cells 
that, in turn, can impact on any subsequent developing/
ongoing immune response [13, 16, 17].
Soluble OX40 (sOX40) may be produced through 
cleavage from cell surface OX40 and/or alternative splicing 
[18-20]. Soluble forms of TNF receptors have antagonistic 
effects on membrane-bound receptors. Therefore, it is 
possible that abnormal activation of T-cells may induce 
alternative splicing of sOX40 in patients with NMO [9, 
12, 21]. However, the function of sOX40 in NMO remains 
unknown.
The OX40 expression level in peripheral white 
blood cells of NMO patients may provide insight into 
immunologic mechanisms related to NMO progression. 
Accordingly, this study was designed to evaluate OX40 
gene expression and serum levels (as sOX40) of the protein 
for potential use in helping in the eventual development of 
more effective targeted treatments against this pathology.
Materials and Methods
Patients and controls
Twenty NMO patients were recruited for the study 
(median age = 31 years, 15 female/5 male; mean disease 
duration = 2.4 years) from the Kashani Hospital of Isfahan 
(Iran). Diagnosis of NMO was confirmed by clinical and 
neurophysiological parameters. All patients met research 
criteria used to define NMO [3], as verified by a hospital 
neurologist. For all patients, both the longitudinally-
extensive transverse myelitis (LETM) as annualized relapse 
rate and the Expanded Disability Status Scale (EDSS) were 
assessed. Cerebral and spinal cord magnetic resonance 
imaging (MRI) were used to evaluate the presence of 
specific NMO-like lesions. As controls, 20 healthy sex-/
age-matched individuals (HC; median age = 32 years, 
15 female/5 male) were also recruited for study. Table 1 
presents the demographic and clinical characteristics of 
all study subjects. 
A total of 5 ml fasting venous blood was taken 
from each individual. Two ml was collected into EDTA-
containing tubes for subsequent use in white blood cell 
RNA extraction. The other 3 ml was collected into a tube 
without anti-coagulant; this material was immediately 
centrifuged (4000 rpm, 6 min, 4°C), and the resultant 
serum was harvested and stored at -20°C for later analysis.
Informed consent: Informed consent has been 
obtained from all individuals included in this study.
Ethical approval: The research related to human 
use has been complied with all the relevant national 
regulations, institutional policies and in accordance the 
tenets of the Helsinki Declaration, and has been approved 
by the ethical committee of Isfahan University of Medical 
Sciences.
Table 1: Characteristics of NMO patient and control subjects.
NMO             Controls
Females/Males 15/5             15/5
Average age at onset
AQ-P4 Ab positive (%)
31                  31 
30                  ---
LETM (%) 60                  ---
Normal brain (MRI) (%) 80                  ---
EDSS (n) 2                     ---
Values are presented as frequencies (percentages) 
LETM: Longitudinally-extensive transverse myelitis, annualized 
relapse rate.
EDSS: Expanded Disability Status Scale.
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RNA extraction and RT-PCR
From each whole blood sample, total RNA was extracted 
from white blood cells using a YTA kit Total RNA 
Purification Mini kit (Yekta Tajhiz, Tehran, Iran), according 
to manufacturer’s protocol. Concentration and integrity of 
total isolated RNA from each sample was assessed using a 
Nanophotometer Pipette System (Helmholtz, Nauenberg, 
Germany) and the material was then stored at -70°C (mean 
concentration was ≈ 80 µg/ml).
From each sample, cDNA was prepared using a 
Thermo Scientific Revert Aid RT Kit containing oligo 
dT primer mixture (Bio-Rad, Watford, UK) according to 
manufacturer protocol. In brief, 11 µl (≈ 0.9 µg) total RNA 
was mixed with 1 µl oligo dT primer, and then incubated 
at 65°C for 5 min). Thereafter, 8 µl Reverse Transcription 
Master Mix (5X Reaction Buffer) and 2X dNTP Mix (both 
Applied Biosystems, Cheshire, UK) was added (on ice), 
and the mixture was incubated for 1 hr at 42°C and then 
10 min at 70°C.
Real-time PCR
qRT-PCR was performed using Syber Green PCR Master 
Mix (Applied Biosystems). Forward and reverse primer 
sequences used for the qRT-PCR reactions (Table 2) 
were designed using Allele ID version 7. Each qPCR was 
performed in a Step One Plus Real-Time PCR system 
(Applied Biosystems). Thermocycler conditions used 
in each case were 95°C for 15 min (initial denaturation) 
followed by 40 cycles of 95°C for 15 sec, 54°C for 60 sec, 
and 72°C for 20 sec, with a final extension of 72°C for 1 
min. All results were evaluated using the 2-DDCt method [22, 
23].
ELISA
sOX40 levels in sera were measured (in duplicate) using 
a human sCD134 (OX40) platinum ELISA kit (eBioscience, 
Vienna, Austria), following manufacturer protocols. 
Optical density (OD) at 450 nm wavelength was recorded 
for each sample using a Hiperion Microplate Reader 
(Rodermark, Germany). To establish seropositivity, 
serum from each NMO patient was also evaluated for 
anti-Aquaporin 4 (AQP4) antibody using an Indirect 
Immunofluorescence Test (IIFT) cell-based assay 
(EUROIMMUN IIFT, Luebeck, Germany).
Statistical analysis
All results are expressed as mean ± SD. Normal distribution 
of all data was determined using a Kolmogorov-Smirnov 
test. A non-parametric Mann-Whitney U-test was applied 
for comparing values between groups. A p-value < 0·05 
was accepted as significant. All analyses were conducted 
using an SPSS 20 package (SPSS Inc., Chicago, IL).
Results
OX40 mRNA expression
OX40 mRNA in the white blood cells of NMO patients was 
found to be significantly (p = 0.001) lower than in control 
individuals’ cells. The average Ct values were 32.1 and 29.7, 
respectively. Within-gender analyses revealed that females 
with NMO had levels significantly (p = 0.041) lower than in 
female control counterparts; average values were 32.8 and 
30.4, respectively. There were no significant differences 
between male NMO and male controls (p = 0.70). In total, 
there appeared to be no correlation between OX40 mRNA 
and age in this group of NMO patients.
Serum sOX40 levels
The ELISA data indicated there were no significant 
differences between sOX40 levels in the serum of NMO 
patients compared with those from healthy controls (p = 
0.37) (Figure 1). The average values were 12.7 and 14.9 ng/
ml, respectively. The current analyses found that median 
sOX40 levels in AQP4 seropositive subjects were higher 
than in seronegative NMO patients, but this difference 
was not significant (p = 0.45) (Figure 2).






OX40    Forward
OX40    Reverse
TGGTGTAACCCAGAAGTG
GTCAACTCCAGGCTTGTA
 Parya Alidadiani et al: Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients     65
Discussion
Several studies have provided evidence for an important 
role of effector T-cells in various steps during the 
pathogenesis of neuromyelitis optica (NMO). Levels of 
interleukin (IL)-17-secreting CD4+ T-cells (TH17 cells) are 
known to be significantly elevated in NMO patients, 
suggesting these autoantigen-specific T-cells might help 
drive some of the pathologies associated with NMO [24]. 
Interestingly, IL-6 is not only elevated in the cerebral-spinal 
fluid (CSF), but also in the sera, of patients with NMO. 
This is important in that IL-6 is involved in development 
of TH17 cells [25]. Serum IL-22 and IL-21 levels are also 
elevated during NMO [26] and so it is not surprising that 
TH22 cell levels have been found to significantly correlate 
with those of TH17 cells in these patients. Certain types 
of T-cells are also found in the lesions that occur in NMO 
patients, though their antigen specificity and function 
have not been characterized [27]. Thus, a variety of 
effector T-cells seem to be potentially required for overall 
NMO development. Whether these are specifically needed 
for disease-related lesion development, or for disrupting 
blood-brain or blood-CSF barriers, or just perhaps for 
creating an inflammatory milieu in situ for anti-AQP4 
antibodies to be operational remains to be determined.
At the factor level, a variety of co-stimulatory 
molecules (such as CD69) have been shown to play 
important roles in the NMO pathogenesis. It is plausible 
to assume that the presence - or absence - of other factors 
may also likely contribute to T-cell activation in NMO 
[5]. OX40 is essential for optimal function of T-cells. For 
example, a role for OX40 signaling in activation of cytolytic 
T-lymphocytes is well established [14]. Expression of OX40 
is also believed to be a factor involved in the ability of 
T-cells to leave the general circulation and enter the CNS 
[28]. In addition, OX40 has an important role in preventing 
T-cell apoptosis by inducing expression of anti-apoptotic 
molecules (such as Bcl-X). When taken together, it is clear 
that OX40 can impact on the size of the effector T-cell pool 
in a host. Accordingly, as critical components of T-cell 
responses, OX40 is likely to be important in the context of 
autoimmunity [29-31].
In this study, it was seen that gene expression of 
OX40 was significantly decreased in the peripheral white 
blood cells of NMO patients. At the same time, circulating 
levels of the soluble form of the OX40 protein (sOX40) was 
unaltered by disease status. This observation contrasts 
with that of another investigations wherein sOX40 levels 
in sera of patients with ALS were decreased compared to 
control values [32]. Other reports have shown that active 
human NMO lesions contained increased numbers of 
CD4+ T-cells expressing the OX40 activation marker, and 
that expression was more profound compared to that seen 
in MS lesions of comparable activity [33]. Recently, it was 
shown that T-cells isolated from the spinal cords of Lewis 
rats with actively-induced EAE (experimental allergic 
encephalomyelitis) expressed OX40 [28]. As such, it is not 
clear why systemic levels of OX40 (specifically, as soluble 
sOX40 form) in NMO patients here were the same as in 
the control subjects. Similarly, it is not readily apparent 
why expression levels of OX40 gene among circulating 
leukocytes in the NMO patients here were decreased in 
comparison to in control subject cells.














G ro u p  o f  s tu d y
Figure 1: Serum sOX40 levels. There were no significant differences 
in sOX40 serum levels when comparing NMO patients with controls 
(p = 0.37). Values shown are means ± SD of 20 subjects/group.
Figure 2: sOX40 serum levels in AQP4 seropositive and -negative 
NMO patients. There were no significant differences between the 
two groups (p = 0.044.). Values shown are means ± SD from 6 
seropositive and 12 seronegative NHO patients. 
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The present study indicated that OX40 gene expression 
in circulating white blood cells was significantly lower 
in NMO females than in cells of corresponding female 
controls. Interestingly, there was no similar male-related 
differential in outcome. While it is known sex hormones 
(including estrogens and androgens) have crucial roles in 
autoimmune diseases [34], it is not clear why there was 
such a bifurcation in outcomes between the male and 
female NMO patients (vs. controls) here.
Lastly, the present study showed OX40/CD134 
expression (serum) was not age-related among the NMO 
patients. It is known that CD134 surface density on CD4+ 
cells was decreased in spinal cords of aging rats and on 
in vitro-stimulated naïve CD4+ splenocytes taken from 
aged rats vs. cells from younger rats [35]. This invites the 
question of if expression of the marker is impacted by 
localization to a given tissue, as opposed to any similar 
influence on T-cells while they remain in the general 
circulation. This specific issue warrants further study.
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